Obsidian Therapeutics, Inc. SEC filings OBX
Obsidian Therapeutics, Inc. has 35 filings in SEC EDGAR's recent list, going back to Apr 22, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 3, 2026 (material agreement, acquisition or sale of assets, results of operations, unregistered share sale, change to shareholder rights, auditor change, change in control, officer or director change, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K/A | Amended current report | Aug 14, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Results of operations, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 3, 2026 | Jul 31, 2026 |
Showing 2 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OBX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2130606
- Former names
- Gazelle Parent, Inc. (until Aug 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.